Literature DB >> 18186522

A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias.

Maria Goldaniga1, Andrea Ferrario, Sergio Cortelazzo, Andrea Guffanti, Enzo Pavone, Achille Ambrosetti, Luigi Marcheselli, Francesca Rossi, Stefano Luminari, Andrea Rossi, Lilla Cro, Massimo Federico, Giorgio Lambertenghi Deliliers, Luca Baldini.   

Abstract

CD5-negative chronic B cell lymphoproliferative disorders in leukemic phase (B-CLPD) are heterogeneous and relatively uncommon pathologies that often lack a histopathological definition because of the absence of accessible pathological tissue. We describe the clinical features and evolution-related variables of 156 patients with CD5/CD10-negative B-CLPD (median age 66 years, range 25-86). The median follow-up was 51 months (range 6-216), and overall 3- and 5-year survival was respectively 87 and 76%; 50 patients needed therapy at diagnosis, 56 during follow-up, and 50 remained untreated until the last control. A combined clinical, histological, cytomorphological, immunophenotypical, and cytogenetic diagnostic approach allowed the complete classification of only a minority of patients as being affected by splenic marginal zone or lymphoplasmacytic lymphoma; the majority of cases remained unclassifiable. Multivariate analysis showed that the clinicohematological variables adversely related to overall survival were serum LDH levels and age, whereas high serum LDH levels, hemoglobin levels of <11 g/dl, and splenomegaly related to treatment-free time (in "wait and see" cases); only splenomegaly related to time to progression (in treated patients). In conclusion, our retrospective study describes the clinical features and variables related to evolution in a large group of patients with CD5/CD10-negative chronic B-cell lymphoid leukemias and underlines the fact that a probable lymphoplasmacytic or marginal zone normal cell origin can be supposed in such leukemic forms, but never surely demonstrated. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18186522     DOI: 10.1002/ajh.21065

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  9 in total

1.  First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.

Authors:  Roberto Castelli; Luigi Bergamaschini; Giorgio Lambertenghi Deliliers
Journal:  Med Oncol       Date:  2017-12-29       Impact factor: 3.064

2.  CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity.

Authors:  Roxana S Dronca; Dragan Jevremovic; Curtis A Hanson; Kari G Rabe; Tait D Shanafelt; William G Morice; Timothy G Call; Neil E Kay; Charles S Collins; Susan M Schwager; Susan L Slager; Clive S Zent
Journal:  Cytometry B Clin Cytom       Date:  2010       Impact factor: 3.058

Review 3.  Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy.

Authors:  Luca Arcaini; Michele Merli; Stefano Volpetti; Sara Rattotti; Manuel Gotti; Francesco Zaja
Journal:  Clin Dev Immunol       Date:  2012-08-26

4.  Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping.

Authors:  E S Costa; C E Pedreira; S Barrena; Q Lecrevisse; J Flores; S Quijano; J Almeida; M del Carmen García-Macias; S Bottcher; J J M Van Dongen; A Orfao
Journal:  Leukemia       Date:  2010-09-16       Impact factor: 11.528

5.  Serum lactate dehydrogenase and survival following cancer diagnosis.

Authors:  Wahyu Wulaningsih; Lars Holmberg; Hans Garmo; Håkan Malmstrom; Mats Lambe; Niklas Hammar; Göran Walldius; Ingmar Jungner; Tony Ng; Mieke Van Hemelrijck
Journal:  Br J Cancer       Date:  2015-10-15       Impact factor: 7.640

6.  Bendamustine and Rituximab, as First Line Treatment, in Intermediate, High Risk Splenic Marginal Zone Lymphomas of Elderly Patients.

Authors:  Roberto Castelli; Antonio Gidaro; Giorgio Lambertenghi Deliliers
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-07-01       Impact factor: 2.576

Review 7.  Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma.

Authors:  Michele Merli; Giuseppe Carli; Luca Arcaini; Carlo Visco
Journal:  World J Gastroenterol       Date:  2016-10-14       Impact factor: 5.742

8.  Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders.

Authors:  Shuhua Yi; Zengjun Li; Dehui Zou; Wenjie Xiong; Heng Li; Rui Cui; Chengwen Li; Yuting Yan; Wei Liu; Rui Lv; Zhen Yu; Weiwei Chen; Yan Xu; Gang An; Huijun Wang; Kun Ru; Tao Cheng; Jianxiang Wang; Lugui Qiu
Journal:  Oncotarget       Date:  2017-12-15

9.  Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report.

Authors:  Kazuya Ishiguro; Yasushi Sasaki; Yoshitake Takagi; Takeshi Niinuma; Hiromu Suzuki; Takashi Tokino; Toshiaki Hayashi; Tohru Takahashi; Tetsuyuki Igarashi; Yoshihiro Matsuno
Journal:  Medicine (Baltimore)       Date:  2020-08-28       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.